Teva – Investorempires.com

Despite price cuts, Teva loses its shine in Israel

Teva reports seventh straight quarter of growth

Teva leapfrogs Check Point as Israel’s most valuable company

Teva settles further price-fixing lawsuits in the US

Teva shareholder sues after $450m US settlement

Teva settles opioid suits in Israel

Teva reports strong Q2 results, raises 2024 forecast

Teva schizophrenia drug Phase III results excite analysts

Teva loss narrows as revenue grows

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 By Investing.com